nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—SLC22A1—hematologic cancer	0.00159	0.775	CrCbGaD
Apraclonidine—Clonidine—ABCB1—hematologic cancer	0.000461	0.225	CrCbGaD
Apraclonidine—Diarrhoea—Gemcitabine—hematologic cancer	0.000179	0.00022	CcSEcCtD
Apraclonidine—Nausea—Thalidomide—hematologic cancer	0.000178	0.000219	CcSEcCtD
Apraclonidine—Dermatitis—Ifosfamide—hematologic cancer	0.000178	0.000219	CcSEcCtD
Apraclonidine—Dizziness—Irinotecan—hematologic cancer	0.000177	0.000218	CcSEcCtD
Apraclonidine—Malaise—Prednisone—hematologic cancer	0.000177	0.000217	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—hematologic cancer	0.000176	0.000217	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—hematologic cancer	0.000176	0.000217	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—hematologic cancer	0.000176	0.000217	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—hematologic cancer	0.000176	0.000216	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—hematologic cancer	0.000176	0.000216	CcSEcCtD
Apraclonidine—Syncope—Prednisone—hematologic cancer	0.000176	0.000216	CcSEcCtD
Apraclonidine—Vomiting—Vincristine—hematologic cancer	0.000175	0.000215	CcSEcCtD
Apraclonidine—Asthenia—Cisplatin—hematologic cancer	0.000175	0.000215	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—hematologic cancer	0.000175	0.000215	CcSEcCtD
Apraclonidine—Fatigue—Triamcinolone—hematologic cancer	0.000174	0.000214	CcSEcCtD
Apraclonidine—Dermatitis—Vincristine—hematologic cancer	0.000173	0.000213	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—hematologic cancer	0.000173	0.000213	CcSEcCtD
Apraclonidine—Pain—Triamcinolone—hematologic cancer	0.000173	0.000213	CcSEcCtD
Apraclonidine—Headache—Vincristine—hematologic cancer	0.000173	0.000212	CcSEcCtD
Apraclonidine—Nausea—Carmustine—hematologic cancer	0.000171	0.000211	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—hematologic cancer	0.000171	0.00021	CcSEcCtD
Apraclonidine—Vomiting—Mitoxantrone—hematologic cancer	0.000171	0.00021	CcSEcCtD
Apraclonidine—Vomiting—Irinotecan—hematologic cancer	0.000171	0.00021	CcSEcCtD
Apraclonidine—Nausea—Alitretinoin—hematologic cancer	0.00017	0.000209	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—hematologic cancer	0.00017	0.000208	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—hematologic cancer	0.00017	0.000208	CcSEcCtD
Apraclonidine—Dermatitis—Irinotecan—hematologic cancer	0.000169	0.000208	CcSEcCtD
Apraclonidine—Dermatitis—Mitoxantrone—hematologic cancer	0.000169	0.000208	CcSEcCtD
Apraclonidine—Headache—Irinotecan—hematologic cancer	0.000168	0.000206	CcSEcCtD
Apraclonidine—Headache—Mitoxantrone—hematologic cancer	0.000168	0.000206	CcSEcCtD
Apraclonidine—Nausea—Ifosfamide—hematologic cancer	0.000168	0.000206	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	0.000167	0.000206	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	0.000167	0.000206	CcSEcCtD
Apraclonidine—Myalgia—Prednisone—hematologic cancer	0.000167	0.000205	CcSEcCtD
Apraclonidine—Feeling abnormal—Triamcinolone—hematologic cancer	0.000167	0.000205	CcSEcCtD
Apraclonidine—Diarrhoea—Cisplatin—hematologic cancer	0.000167	0.000205	CcSEcCtD
Apraclonidine—Vomiting—Gemcitabine—hematologic cancer	0.000166	0.000204	CcSEcCtD
Apraclonidine—Insomnia—Betamethasone—hematologic cancer	0.000166	0.000204	CcSEcCtD
Apraclonidine—Insomnia—Dexamethasone—hematologic cancer	0.000166	0.000204	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—hematologic cancer	0.000166	0.000204	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	0.000166	0.000204	CcSEcCtD
Apraclonidine—Paraesthesia—Dexamethasone—hematologic cancer	0.000165	0.000203	CcSEcCtD
Apraclonidine—Paraesthesia—Betamethasone—hematologic cancer	0.000165	0.000203	CcSEcCtD
Apraclonidine—Discomfort—Prednisone—hematologic cancer	0.000165	0.000202	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—hematologic cancer	0.000165	0.000202	CcSEcCtD
Apraclonidine—Dermatitis—Gemcitabine—hematologic cancer	0.000165	0.000202	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—hematologic cancer	0.000164	0.000202	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—hematologic cancer	0.000164	0.000202	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—hematologic cancer	0.000164	0.000201	CcSEcCtD
Apraclonidine—Headache—Gemcitabine—hematologic cancer	0.000164	0.000201	CcSEcCtD
Apraclonidine—Nausea—Vincristine—hematologic cancer	0.000164	0.000201	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—hematologic cancer	0.000163	0.000201	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—hematologic cancer	0.000163	0.0002	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisolone—hematologic cancer	0.000162	0.000199	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—hematologic cancer	0.000162	0.000199	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—hematologic cancer	0.00016	0.000197	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—hematologic cancer	0.00016	0.000197	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—hematologic cancer	0.00016	0.000197	CcSEcCtD
Apraclonidine—Oedema—Prednisone—hematologic cancer	0.00016	0.000196	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—hematologic cancer	0.00016	0.000196	CcSEcCtD
Apraclonidine—Nausea—Mitoxantrone—hematologic cancer	0.000159	0.000196	CcSEcCtD
Apraclonidine—Nausea—Irinotecan—hematologic cancer	0.000159	0.000196	CcSEcCtD
Apraclonidine—Infection—Prednisone—hematologic cancer	0.000159	0.000195	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—hematologic cancer	0.000159	0.000195	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000159	0.000195	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000159	0.000195	CcSEcCtD
Apraclonidine—Fatigue—Betamethasone—hematologic cancer	0.000158	0.000194	CcSEcCtD
Apraclonidine—Fatigue—Dexamethasone—hematologic cancer	0.000158	0.000194	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—hematologic cancer	0.000158	0.000194	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—hematologic cancer	0.000157	0.000193	CcSEcCtD
Apraclonidine—Pain—Dexamethasone—hematologic cancer	0.000157	0.000193	CcSEcCtD
Apraclonidine—Pain—Betamethasone—hematologic cancer	0.000157	0.000193	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—hematologic cancer	0.000157	0.000193	CcSEcCtD
Apraclonidine—Nervous system disorder—Prednisone—hematologic cancer	0.000157	0.000193	CcSEcCtD
Apraclonidine—Skin disorder—Prednisone—hematologic cancer	0.000155	0.000191	CcSEcCtD
Apraclonidine—Nausea—Gemcitabine—hematologic cancer	0.000155	0.000191	CcSEcCtD
Apraclonidine—Vomiting—Cisplatin—hematologic cancer	0.000155	0.00019	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—hematologic cancer	0.000154	0.00019	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—hematologic cancer	0.000154	0.000189	CcSEcCtD
Apraclonidine—Dermatitis—Cisplatin—hematologic cancer	0.000153	0.000188	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—hematologic cancer	0.000153	0.000188	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—hematologic cancer	0.000153	0.000188	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—hematologic cancer	0.000152	0.000187	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—hematologic cancer	0.000152	0.000187	CcSEcCtD
Apraclonidine—Feeling abnormal—Dexamethasone—hematologic cancer	0.000151	0.000186	CcSEcCtD
Apraclonidine—Feeling abnormal—Betamethasone—hematologic cancer	0.000151	0.000186	CcSEcCtD
Apraclonidine—Tension—Epirubicin—hematologic cancer	0.00015	0.000185	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dexamethasone—hematologic cancer	0.00015	0.000184	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Betamethasone—hematologic cancer	0.00015	0.000184	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—hematologic cancer	0.00015	0.000184	CcSEcCtD
Apraclonidine—Hypersensitivity—Triamcinolone—hematologic cancer	0.000149	0.000183	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—hematologic cancer	0.000149	0.000183	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—hematologic cancer	0.000148	0.000182	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—hematologic cancer	0.000148	0.000181	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—hematologic cancer	0.000148	0.000181	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—hematologic cancer	0.000147	0.00018	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Prednisone—hematologic cancer	0.000146	0.000179	CcSEcCtD
Apraclonidine—Dizziness—Prednisolone—hematologic cancer	0.000145	0.000179	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—hematologic cancer	0.000145	0.000179	CcSEcCtD
Apraclonidine—Asthenia—Triamcinolone—hematologic cancer	0.000145	0.000178	CcSEcCtD
Apraclonidine—Abdominal pain—Betamethasone—hematologic cancer	0.000145	0.000178	CcSEcCtD
Apraclonidine—Abdominal pain—Dexamethasone—hematologic cancer	0.000145	0.000178	CcSEcCtD
Apraclonidine—Nausea—Cisplatin—hematologic cancer	0.000145	0.000178	CcSEcCtD
Apraclonidine—Insomnia—Prednisone—hematologic cancer	0.000145	0.000178	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—hematologic cancer	0.000144	0.000177	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisone—hematologic cancer	0.000144	0.000176	CcSEcCtD
Apraclonidine—Pruritus—Triamcinolone—hematologic cancer	0.000143	0.000176	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—hematologic cancer	0.000143	0.000175	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—hematologic cancer	0.000142	0.000175	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—hematologic cancer	0.000142	0.000174	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—hematologic cancer	0.000142	0.000174	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—hematologic cancer	0.000141	0.000173	CcSEcCtD
Apraclonidine—Headache—Etoposide—hematologic cancer	0.00014	0.000172	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—hematologic cancer	0.000139	0.000171	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—hematologic cancer	0.000139	0.000171	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—hematologic cancer	0.000139	0.000171	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—hematologic cancer	0.000139	0.000171	CcSEcCtD
Apraclonidine—Dermatitis—Prednisolone—hematologic cancer	0.000139	0.00017	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	0.000138	0.00017	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—hematologic cancer	0.000138	0.00017	CcSEcCtD
Apraclonidine—Fatigue—Prednisone—hematologic cancer	0.000138	0.000169	CcSEcCtD
Apraclonidine—Headache—Prednisolone—hematologic cancer	0.000138	0.000169	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—hematologic cancer	0.000138	0.000169	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—hematologic cancer	0.000138	0.000169	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—hematologic cancer	0.000137	0.000169	CcSEcCtD
Apraclonidine—Constipation—Prednisone—hematologic cancer	0.000137	0.000168	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—hematologic cancer	0.000135	0.000166	CcSEcCtD
Apraclonidine—Dizziness—Triamcinolone—hematologic cancer	0.000134	0.000164	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—hematologic cancer	0.000134	0.000164	CcSEcCtD
Apraclonidine—Infection—Methotrexate—hematologic cancer	0.000133	0.000163	CcSEcCtD
Apraclonidine—Nausea—Etoposide—hematologic cancer	0.000133	0.000163	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisone—hematologic cancer	0.000132	0.000162	CcSEcCtD
Apraclonidine—Asthenia—Betamethasone—hematologic cancer	0.000132	0.000162	CcSEcCtD
Apraclonidine—Asthenia—Dexamethasone—hematologic cancer	0.000132	0.000162	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—hematologic cancer	0.000132	0.000162	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—hematologic cancer	0.000131	0.000161	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Prednisone—hematologic cancer	0.000131	0.000161	CcSEcCtD
Apraclonidine—Nausea—Prednisolone—hematologic cancer	0.000131	0.000161	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—hematologic cancer	0.00013	0.00016	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—hematologic cancer	0.00013	0.00016	CcSEcCtD
Apraclonidine—Pruritus—Dexamethasone—hematologic cancer	0.00013	0.00016	CcSEcCtD
Apraclonidine—Pruritus—Betamethasone—hematologic cancer	0.00013	0.00016	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—hematologic cancer	0.00013	0.000159	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	0.00013	0.000159	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—hematologic cancer	0.000129	0.000158	CcSEcCtD
Apraclonidine—Vomiting—Triamcinolone—hematologic cancer	0.000129	0.000158	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—hematologic cancer	0.000128	0.000157	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—hematologic cancer	0.000128	0.000157	CcSEcCtD
Apraclonidine—Dermatitis—Triamcinolone—hematologic cancer	0.000127	0.000157	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—hematologic cancer	0.000127	0.000156	CcSEcCtD
Apraclonidine—Headache—Triamcinolone—hematologic cancer	0.000127	0.000156	CcSEcCtD
Apraclonidine—Abdominal pain—Prednisone—hematologic cancer	0.000126	0.000155	CcSEcCtD
Apraclonidine—Diarrhoea—Dexamethasone—hematologic cancer	0.000126	0.000154	CcSEcCtD
Apraclonidine—Diarrhoea—Betamethasone—hematologic cancer	0.000126	0.000154	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—hematologic cancer	0.000125	0.000154	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—hematologic cancer	0.000125	0.000154	CcSEcCtD
Apraclonidine—Infection—Epirubicin—hematologic cancer	0.000124	0.000153	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—hematologic cancer	0.000123	0.000151	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	0.000122	0.00015	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—hematologic cancer	0.000121	0.000149	CcSEcCtD
Apraclonidine—Dizziness—Betamethasone—hematologic cancer	0.000121	0.000149	CcSEcCtD
Apraclonidine—Dizziness—Dexamethasone—hematologic cancer	0.000121	0.000149	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—hematologic cancer	0.000121	0.000149	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—hematologic cancer	0.000121	0.000148	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—hematologic cancer	0.000121	0.000148	CcSEcCtD
Apraclonidine—Nausea—Triamcinolone—hematologic cancer	0.00012	0.000148	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—hematologic cancer	0.00012	0.000147	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	0.00012	0.000147	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—hematologic cancer	0.000119	0.000147	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—hematologic cancer	0.000119	0.000146	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—hematologic cancer	0.000119	0.000146	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—hematologic cancer	0.000118	0.000145	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisone—hematologic cancer	0.000118	0.000145	CcSEcCtD
Apraclonidine—Vomiting—Dexamethasone—hematologic cancer	0.000117	0.000143	CcSEcCtD
Apraclonidine—Vomiting—Betamethasone—hematologic cancer	0.000117	0.000143	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—hematologic cancer	0.000116	0.000142	CcSEcCtD
Apraclonidine—Dermatitis—Dexamethasone—hematologic cancer	0.000116	0.000142	CcSEcCtD
Apraclonidine—Dermatitis—Betamethasone—hematologic cancer	0.000116	0.000142	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000115	0.000142	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—hematologic cancer	0.000115	0.000142	CcSEcCtD
Apraclonidine—Headache—Betamethasone—hematologic cancer	0.000115	0.000141	CcSEcCtD
Apraclonidine—Headache—Dexamethasone—hematologic cancer	0.000115	0.000141	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—hematologic cancer	0.000115	0.000141	CcSEcCtD
Apraclonidine—Asthenia—Prednisone—hematologic cancer	0.000115	0.000141	CcSEcCtD
Apraclonidine—Pain—Methotrexate—hematologic cancer	0.000114	0.00014	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	0.000114	0.00014	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—hematologic cancer	0.000113	0.000139	CcSEcCtD
Apraclonidine—Pruritus—Prednisone—hematologic cancer	0.000113	0.000139	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—hematologic cancer	0.000113	0.000139	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—hematologic cancer	0.000112	0.000138	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—hematologic cancer	0.000112	0.000138	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—hematologic cancer	0.000111	0.000137	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—hematologic cancer	0.000111	0.000137	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—hematologic cancer	0.00011	0.000135	CcSEcCtD
Apraclonidine—Diarrhoea—Prednisone—hematologic cancer	0.000109	0.000134	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—hematologic cancer	0.000109	0.000134	CcSEcCtD
Apraclonidine—Nausea—Dexamethasone—hematologic cancer	0.000109	0.000134	CcSEcCtD
Apraclonidine—Nausea—Betamethasone—hematologic cancer	0.000109	0.000134	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000108	0.000133	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—hematologic cancer	0.000108	0.000132	CcSEcCtD
Apraclonidine—Pain—Epirubicin—hematologic cancer	0.000107	0.000131	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—hematologic cancer	0.000107	0.000131	CcSEcCtD
Apraclonidine—Dizziness—Prednisone—hematologic cancer	0.000106	0.00013	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—hematologic cancer	0.000106	0.00013	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	0.000105	0.00013	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—hematologic cancer	0.000105	0.000129	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—hematologic cancer	0.000104	0.000128	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—hematologic cancer	0.000103	0.000127	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—hematologic cancer	0.000103	0.000127	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—hematologic cancer	0.000103	0.000126	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—hematologic cancer	0.000102	0.000126	CcSEcCtD
Apraclonidine—Vomiting—Prednisone—hematologic cancer	0.000102	0.000125	CcSEcCtD
Apraclonidine—Dermatitis—Prednisone—hematologic cancer	0.000101	0.000124	CcSEcCtD
Apraclonidine—Headache—Prednisone—hematologic cancer	0.0001	0.000123	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	9.99e-05	0.000123	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—hematologic cancer	9.98e-05	0.000123	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—hematologic cancer	9.89e-05	0.000122	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—hematologic cancer	9.89e-05	0.000122	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—hematologic cancer	9.89e-05	0.000121	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—hematologic cancer	9.84e-05	0.000121	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—hematologic cancer	9.59e-05	0.000118	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—hematologic cancer	9.53e-05	0.000117	CcSEcCtD
Apraclonidine—Nausea—Prednisone—hematologic cancer	9.5e-05	0.000117	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—hematologic cancer	9.46e-05	0.000116	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—hematologic cancer	9.45e-05	0.000116	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—hematologic cancer	9.21e-05	0.000113	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—hematologic cancer	9.15e-05	0.000112	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—hematologic cancer	9.14e-05	0.000112	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—hematologic cancer	8.97e-05	0.00011	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—hematologic cancer	8.85e-05	0.000109	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—hematologic cancer	8.84e-05	0.000109	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—hematologic cancer	8.56e-05	0.000105	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—hematologic cancer	8.52e-05	0.000105	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—hematologic cancer	8.5e-05	0.000104	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—hematologic cancer	8.42e-05	0.000103	CcSEcCtD
Apraclonidine—Headache—Methotrexate—hematologic cancer	8.37e-05	0.000103	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—hematologic cancer	8.3e-05	0.000102	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—hematologic cancer	8.27e-05	0.000102	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—hematologic cancer	8.19e-05	0.000101	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—hematologic cancer	7.95e-05	9.77e-05	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—hematologic cancer	7.94e-05	9.75e-05	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—hematologic cancer	7.92e-05	9.73e-05	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—hematologic cancer	7.88e-05	9.68e-05	CcSEcCtD
Apraclonidine—Headache—Epirubicin—hematologic cancer	7.83e-05	9.63e-05	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—hematologic cancer	7.65e-05	9.4e-05	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—hematologic cancer	7.43e-05	9.13e-05	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—hematologic cancer	7.36e-05	9.04e-05	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—hematologic cancer	7.29e-05	8.96e-05	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—hematologic cancer	7.25e-05	8.91e-05	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—hematologic cancer	6.87e-05	8.44e-05	CcSEcCtD
Apraclonidine—ADRA2A—Signaling Pathways—FGF1—hematologic cancer	2.32e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK14—hematologic cancer	2.31e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CD80—hematologic cancer	2.3e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CG—hematologic cancer	2.29e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KIT—hematologic cancer	2.29e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—NRAS—hematologic cancer	2.29e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FOXO1—hematologic cancer	2.28e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2—hematologic cancer	2.28e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDGFRB—hematologic cancer	2.28e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ESR1—hematologic cancer	2.27e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CB—hematologic cancer	2.26e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTPN11—hematologic cancer	2.25e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CD—hematologic cancer	2.25e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	2.25e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDGFRA—hematologic cancer	2.25e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FN1—hematologic cancer	2.24e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCG—hematologic cancer	2.24e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JAK1—hematologic cancer	2.24e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	2.23e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—hematologic cancer	2.22e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TERT—hematologic cancer	2.22e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—HRAS—hematologic cancer	2.22e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NFKBIA—hematologic cancer	2.21e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BAD—hematologic cancer	2.21e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK3—hematologic cancer	2.2e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH1—hematologic cancer	2.19e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CREB1—hematologic cancer	2.18e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	2.17e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BRAF—hematologic cancer	2.16e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CD80—hematologic cancer	2.15e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CG—hematologic cancer	2.14e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KIT—hematologic cancer	2.14e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—NRAS—hematologic cancer	2.14e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—hematologic cancer	2.14e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6R—hematologic cancer	2.13e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3R1—hematologic cancer	2.13e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CREBBP—hematologic cancer	2.13e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	2.12e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTPN11—hematologic cancer	2.11e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	2.09e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CG—hematologic cancer	2.08e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	2.07e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TERT—hematologic cancer	2.07e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK3—hematologic cancer	2.05e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	2.04e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CREB1—hematologic cancer	2.04e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAP2K1—hematologic cancer	2.03e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	2.02e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CD—hematologic cancer	2.02e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	2.02e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BRAF—hematologic cancer	2.01e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	2e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—hematologic cancer	2e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6R—hematologic cancer	1.99e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CREBBP—hematologic cancer	1.99e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	1.98e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—KRAS—hematologic cancer	1.97e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	1.97e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CB—hematologic cancer	1.96e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—hematologic cancer	1.96e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FN1—hematologic cancer	1.96e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BAD—hematologic cancer	1.93e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	1.93e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGF2—hematologic cancer	1.93e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CREBBP—hematologic cancer	1.93e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	1.92e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3R1—hematologic cancer	1.9e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAP2K1—hematologic cancer	1.9e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	1.9e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CD—hematologic cancer	1.88e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	1.88e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CD80—hematologic cancer	1.88e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KIT—hematologic cancer	1.87e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	1.87e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	1.87e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—hematologic cancer	1.87e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	1.85e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—KRAS—hematologic cancer	1.84e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	1.84e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	1.84e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CD—hematologic cancer	1.83e-05	9.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FN1—hematologic cancer	1.82e-05	9.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	1.81e-05	9.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	1.81e-05	9.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—hematologic cancer	1.81e-05	9.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGF2—hematologic cancer	1.8e-05	9.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BAD—hematologic cancer	1.8e-05	9.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	1.8e-05	9.76e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	1.79e-05	9.74e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	1.78e-05	9.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	1.78e-05	9.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3R1—hematologic cancer	1.78e-05	9.66e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	1.76e-05	9.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	1.76e-05	9.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	1.76e-05	9.55e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	1.74e-05	9.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CD80—hematologic cancer	1.74e-05	9.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	1.74e-05	9.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KIT—hematologic cancer	1.74e-05	9.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	1.74e-05	9.45e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	1.74e-05	9.45e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	1.74e-05	9.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JAK2—hematologic cancer	1.73e-05	9.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3R1—hematologic cancer	1.73e-05	9.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	1.71e-05	9.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTEN—hematologic cancer	1.7e-05	9.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—hematologic cancer	1.69e-05	9.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MDM2—hematologic cancer	1.69e-05	9.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	1.68e-05	9.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	1.67e-05	9.05e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	1.66e-05	9e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	1.66e-05	9e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	1.65e-05	8.96e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	1.65e-05	8.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MTOR—hematologic cancer	1.64e-05	8.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CB—hematologic cancer	1.64e-05	8.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	1.64e-05	8.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	1.63e-05	8.86e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.63e-05	8.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	1.62e-05	8.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—EP300—hematologic cancer	1.62e-05	8.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	1.62e-05	8.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	1.62e-05	8.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2—hematologic cancer	1.61e-05	8.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	1.61e-05	8.77e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	1.61e-05	8.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	1.61e-05	8.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CB—hematologic cancer	1.6e-05	8.66e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	1.58e-05	8.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	1.57e-05	8.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JUN—hematologic cancer	1.57e-05	8.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	1.57e-05	8.52e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	1.56e-05	8.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	1.54e-05	8.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	1.54e-05	8.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	1.53e-05	8.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	1.52e-05	8.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	1.52e-05	8.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	1.52e-05	8.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.52e-05	8.23e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	1.51e-05	8.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	1.51e-05	8.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2—hematologic cancer	1.51e-05	8.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	1.5e-05	8.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	1.5e-05	8.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	1.49e-05	8.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	1.48e-05	8.05e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.48e-05	8.05e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	1.48e-05	8.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	1.47e-05	7.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JUN—hematologic cancer	1.47e-05	7.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	1.47e-05	7.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EP300—hematologic cancer	1.45e-05	7.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	1.45e-05	7.85e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	1.44e-05	7.8e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	1.44e-05	7.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	1.42e-05	7.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	1.42e-05	7.71e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SRC—hematologic cancer	1.41e-05	7.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	1.4e-05	7.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	1.39e-05	7.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	1.38e-05	7.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTEN—hematologic cancer	1.38e-05	7.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.38e-05	7.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	1.37e-05	7.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	1.37e-05	7.45e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	1.37e-05	7.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	1.36e-05	7.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	1.36e-05	7.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EP300—hematologic cancer	1.35e-05	7.35e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	1.35e-05	7.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	1.33e-05	7.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	1.33e-05	7.24e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	1.33e-05	7.24e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	1.32e-05	7.17e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2—hematologic cancer	1.32e-05	7.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SRC—hematologic cancer	1.32e-05	7.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—EP300—hematologic cancer	1.31e-05	7.14e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	1.31e-05	7.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	1.3e-05	7.05e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	1.29e-05	6.98e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	1.28e-05	6.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	1.28e-05	6.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	1.27e-05	6.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	1.27e-05	6.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	1.27e-05	6.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	1.26e-05	6.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	1.26e-05	6.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	1.25e-05	6.8e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	1.24e-05	6.75e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	1.24e-05	6.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.24e-05	6.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.23e-05	6.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.23e-05	6.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.22e-05	6.62e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.21e-05	6.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	1.21e-05	6.58e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.21e-05	6.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—hematologic cancer	1.2e-05	6.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.19e-05	6.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.19e-05	6.47e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.18e-05	6.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—hematologic cancer	1.18e-05	6.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	1.18e-05	6.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.17e-05	6.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.16e-05	6.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.15e-05	6.26e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.15e-05	6.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.13e-05	6.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.12e-05	6.11e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.12e-05	6.09e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.11e-05	6.03e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.11e-05	6.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.1e-05	5.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	1.09e-05	5.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.07e-05	5.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.07e-05	5.81e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.06e-05	5.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.04e-05	5.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.04e-05	5.63e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.03e-05	5.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.03e-05	5.6e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1.03e-05	5.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.03e-05	5.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	1e-05	5.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	9.92e-06	5.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	9.85e-06	5.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—hematologic cancer	9.78e-06	5.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	9.72e-06	5.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—hematologic cancer	9.68e-06	5.26e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	9.58e-06	5.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	9.56e-06	5.19e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	9.53e-06	5.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	9.49e-06	5.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	9.26e-06	5.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—hematologic cancer	8.86e-06	4.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	8.85e-06	4.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	8.76e-06	4.75e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	8.75e-06	4.75e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	8.47e-06	4.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	8.18e-06	4.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	8.13e-06	4.42e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	8.1e-06	4.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—hematologic cancer	7.94e-06	4.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	7.87e-06	4.27e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	7.75e-06	4.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	7.52e-06	4.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	7.2e-06	3.91e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	7.15e-06	3.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	6.64e-06	3.61e-05	CbGpPWpGaD
